Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ResMed (RMD) Share Price
Media coverage about ResMed (NYSE:RMD) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ResMed earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 44.4869743300891 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Fisher & Paykel says UK court rules rival Resmed’s patent is invalid (RMD, FPH) (markets.businessinsider.com)
- ResMed : Says Considers Appeal On U.K. Case With Fisher & Paykel (4-traders.com)
- Statement by ResMed on United Kingdom Case with Fisher & Paykel (finance.yahoo.com)
- ETFs with exposure to ResMed, Inc. : November 13, 2017 (finance.yahoo.com)
- ResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 Shares (americanbankingnews.com)
A number of equities research analysts have recently issued reports on RMD shares. BidaskClub lowered shares of ResMed from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Bank of America Corporation lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Credit Suisse Group lowered shares of ResMed from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 2nd. Finally, Needham & Company LLC restated a “sell” rating on shares of ResMed in a research note on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $67.57.
Shares of ResMed (NYSE RMD) traded up $0.03 during trading hours on Thursday, hitting $84.25. 497,600 shares of the company were exchanged, compared to its average volume of 870,466. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. ResMed has a twelve month low of $57.45 and a twelve month high of $87.81. The company has a market cap of $11,951.15, a P/E ratio of 29.34, a PEG ratio of 1.87 and a beta of 0.79.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The business had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. During the same quarter in the prior year, the firm earned $0.62 EPS. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. analysts expect that ResMed will post 3 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be given a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.66%. The ex-dividend date is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is 56.68%.
In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $84.50, for a total value of $105,625.00. Following the completion of the transaction, the chief financial officer now owns 71,772 shares in the company, valued at approximately $6,064,734. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $76.74, for a total transaction of $1,534,800.00. Following the completion of the transaction, the director now owns 314,800 shares of the company’s stock, valued at approximately $24,157,752. The disclosure for this sale can be found here. In the last 90 days, insiders sold 201,234 shares of company stock valued at $16,339,637. 1.77% of the stock is owned by insiders.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.